BioXcel Therapeutics, Inc. (BTAI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

BioXcel Therapeutics, Inc. (BTAI) Healthcare & Pipeline Overview

BioXcel Therapeutics is a commercial-stage biopharmaceutical firm leveraging AI to innovate neuroscience and immuno-oncology treatments. Its lead product, IGALMI, addresses acute agitation, while its pipeline targets conditions like Alzheimer's agitation and certain cancers, positioning it within a competitive biotechnology landscape.

What Is the Investment Thesis for BTAI?

BioXcel Therapeutics presents a high-risk, high-reward investment opportunity. The company's commercial product, IGALMI, addresses a significant unmet need in the treatment of acute agitation, offering a novel sublingual formulation. However, the company's profitability is a concern, with a profit margin of -10887.4%. Growth catalysts include the potential expansion of IGALMI's label to include agitation in Alzheimer's disease and other indications, as well as the advancement of BXCL701 in immuno-oncology. The company's success hinges on the successful commercialization of IGALMI and the positive clinical trial results for its pipeline candidates. Investors should carefully consider the risks associated with the company's financial position and the inherent uncertainties in drug development.

Based on FMP financials and quantitative analysis

BTAI Key Highlights

IGALMI is the first and only sublingual film approved for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults.

• Gross margin of 51.2% indicates potential for profitability as sales of IGALMI increase.
• The company's pipeline includes BXCL501 for agitation in Alzheimer's disease, representing a significant market opportunity.
• BXCL701, an investigational immuno-oncology agent, targets aggressive forms of prostate cancer and advanced solid tumors.
• Market Cap of $25.6M reflects the company's current valuation and growth potential.

Who Are BTAI's Competitors?

BTAI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are BTAI's Key Strengths?

Novel AI-driven drug re-innovation approach.

• Commercial product (IGALMI) with FDA approval.
• Pipeline of potential therapies for unmet medical needs.
• Experienced management team with expertise in drug development and commercialization.

What Are BTAI's Weaknesses?

Limited financial resources.

• Dependence on the success of IGALMI and pipeline products.
• Small salesforce.
• Negative profit margin.

What Could Drive BTAI Stock Higher?

Data readouts from clinical trials evaluating BXCL501 for agitation in Alzheimer's disease.

• Progress updates on the development of BXCL701 in immuno-oncology.
• Continued commercialization and market penetration of IGALMI.
• Potential strategic partnerships or licensing agreements.

What Are the Key Risks for BTAI?

Financial-distress signal — its Altman Z-Score of -46.87 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures for pipeline products.
• Regulatory delays or rejections.
• Competition from established pharmaceutical companies.
• Dependence on the success of IGALMI.
• Limited financial resources.

What Are the Growth Opportunities for BTAI?

• Expansion of IGALMI's Label: A significant growth opportunity lies in expanding the approved indications for IGALMI (BXCL501). Currently approved for acute agitation associated with schizophrenia or bipolar I or II disorder, ongoing clinical trials are evaluating its efficacy in treating agitation in Alzheimer's disease patients. Success in these trials could significantly broaden IGALMI's market reach, tapping into the large and underserved population of Alzheimer's patients experiencing agitation.
• Advancement of BXCL701 in Immuno-Oncology: BXCL701, an investigational, orally administered, systemic innate immunity activator, represents another key growth driver. This drug is being developed for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The immuno-oncology market is experiencing rapid growth, and BXCL701 has the potential to address a significant unmet need in patients who do not respond to existing therapies. Positive clinical trial results and subsequent regulatory approval could drive substantial revenue growth for BioXcel.
• Development of BXCL502 for Chronic Agitation in Dementia: The development of BXCL502 as a potential therapy for chronic agitation in dementia presents a further growth opportunity. Chronic agitation is a common and debilitating symptom of dementia, and there are limited treatment options available. If BXCL502 proves to be safe and effective in clinical trials, it could capture a significant share of the dementia therapeutics market, which is expected to grow substantially in the coming years due to the aging global population.
• Strategic Partnerships and Licensing Agreements: BioXcel can pursue strategic partnerships and licensing agreements to expand the reach of its products and pipeline candidates. Collaborating with larger pharmaceutical companies could provide access to additional resources, expertise, and distribution networks. Licensing agreements could generate upfront payments, milestone payments, and royalties, providing a significant source of revenue for BioXcel. These partnerships can accelerate the development and commercialization of its therapies, maximizing their market potential.
• Geographic Expansion: BioXcel can expand its geographic reach by seeking regulatory approval and commercializing its products in new markets outside of the United States. The global market for treatments for psychiatric disorders and cancer is substantial, and expanding into new regions could significantly increase BioXcel's revenue. This expansion would require navigating different regulatory landscapes and establishing distribution networks in each new market, but the potential rewards are significant.

What Threats Does BTAI Face?

• Competition from established pharmaceutical companies.
• Regulatory hurdles and clinical trial failures.
• Patent expiration and generic competition.
• Product liability claims.

What Are BTAI's Competitive Advantages?

• Proprietary AI platform for drug re-innovation.
• Patent protection for IGALMI and other pipeline products.
• First-mover advantage with IGALMI as the first sublingual film for acute agitation.
• Clinical data supporting the efficacy and safety of IGALMI and other pipeline products.

What Does BTAI Do?

BioXcel Therapeutics, Inc., founded in 2017 and headquartered in New Haven, Connecticut, is a biopharmaceutical company focused on utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology. The company employs a drug re-innovation approach, leveraging existing approved drugs and clinically validated product candidates in conjunction with big data and proprietary machine learning algorithms to identify new therapeutic indications. BioXcel's commercial product, IGALMI (dexmedetomidine), is a sublingual film formulation for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. Beyond IGALMI, BioXcel continues to conduct clinical trials evaluating BXCL501 (IGALMI) for the treatment of agitation in Alzheimer's disease patients, as an adjunctive treatment for major depressive disorder, and for agitation associated with bipolar disorders and schizophrenia in community settings. The company is also developing BXCL502 as a potential therapy for chronic agitation in dementia. Furthermore, BXCL701, an investigational, orally administered, systemic innate immunity activator, is being developed for the treatment of aggressive forms of prostate cancer and advanced solid tumors that are refractory or treatment naïve to checkpoint inhibitors. The company's strategy involves identifying and developing novel applications for existing drugs, potentially reducing development time and risk compared to traditional drug discovery processes. With a relatively small team of 37 employees, BioXcel is focused on leveraging technology and strategic partnerships to advance its pipeline and commercialize its products.

What Products and Services Does BTAI Offer?

• Develops drugs using artificial intelligence to identify new therapeutic applications.
• Commercializes IGALMI, a sublingual film for acute agitation associated with schizophrenia or bipolar disorder.
• Conducts clinical trials to expand the use of IGALMI to treat agitation in Alzheimer's disease.
• Develops BXCL502 as a potential therapy for chronic agitation in dementia.
• Develops BXCL701 as an immuno-oncology treatment for aggressive prostate cancer and advanced solid tumors.
• Leverages existing approved drugs and clinically validated product candidates to reduce development time and risk.

How Does BTAI Make Money?

• Develops and commercializes pharmaceutical products.
• Generates revenue through sales of IGALMI.
• Out-licenses or partners with other companies for development and commercialization of pipeline products.
• Utilizes AI and machine learning to identify new drug targets and therapeutic applications.

What Industry Does BTAI Operate In?

BioXcel Therapeutics operates within the biotechnology industry, a sector characterized by high innovation, intense competition, and significant regulatory oversight. The market for treatments for psychiatric disorders, such as schizophrenia, bipolar disorder, and Alzheimer's disease, is substantial and growing, driven by an aging population and increasing awareness of mental health issues. The immuno-oncology market is also experiencing rapid growth, with new therapies targeting the body's immune system to fight cancer. BioXcel's AI-driven drug re-innovation approach positions it as a potential disruptor in the industry, offering a faster and more cost-effective way to develop new therapies.

Who Are BTAI's Key Customers?

• Adults with schizophrenia or bipolar I or II disorder experiencing acute agitation.
• Healthcare providers who prescribe and administer IGALMI.
• Patients with Alzheimer's disease experiencing agitation (potential future customer segment).
• Patients with aggressive forms of prostate cancer and advanced solid tumors (potential future customer segment).

Company Profile

BioXcel Therapeutics, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in New Haven, US. The company is led by CEO Vimal D. Mehta. BTAI has traded publicly since 2018.

BioXcel Therapeutics, Inc. Financial Trajectory

BioXcel Therapeutics, Inc. (BTAI) reported $182K in revenue for Q2 2026, a decline of 11.7% compared to the prior quarter. The company recorded a net loss of $14.7M, with diluted EPS of $-0.49. Revenue has contracted over three consecutive quarters, which investors in this micro-cap Healthcare stock should monitor closely. Across the four most recent quarters, BTAI averaged $-1.19 in diluted EPS.

How BioXcel Therapeutics, Inc. Is Valued

BioXcel Therapeutics, Inc. carries a market capitalization of $25.6M, placing it in the micro-cap category. Relative to its peer group, BTAI's quantitative score of 18/100 is below the peer average of 84/100.

Return on equity for BioXcel Therapeutics, Inc. stands at 0.0%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -86.8%, showing how much profit it generates from its asset base. Its free cash flow yield is 0.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.62 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 0.0%, the inverse of the P/E and a quick read on earnings relative to price.

BioXcel Therapeutics, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -46.87 places it in the distress zone, a signal of elevated financial risk.

Wall Street analysts project BioXcel Therapeutics, Inc. revenue of about $2.0M for fiscal 2026, with EPS near $-1.90.

BTAI Financials

BTAI Latest News

BTAI Analyst Consensus

BTAI MoonshotScore

Common Questions About BTAI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources